• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2-氨基丙-1-烯-1,1,3-三腈衍生的吡啶和螺吡啶衍生物的合成及其 c-Met 激酶抑制活性和抗增殖活性评价。

Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations.

机构信息

Department of Chemistry, Faculty of Science, Cairo University, Giza, Eritrea.

Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hail, Hail, Kingdom of Saudi Arabia.

出版信息

Anticancer Agents Med Chem. 2018 Feb 7;17(14):1951-1962. doi: 10.2174/1871520617666170725153523.

DOI:10.2174/1871520617666170725153523
PMID:28745236
Abstract

BACKGROUND

Among a wide range of pyridines, 3-cyanopyridines acquired a special attention due to their wide range of pharmacological activities especially the therapeutic activities. Many pharmacological drugs containing the pyridine nucleus were known in the market.

OBJECTIVE

The aim of this work was to synthesize target molecules not only possess anti-tumor activities but also kinase inhibitors. To achieve this goal, our strategy was to synthesize a series of 3-cyanopyridine derivatives using 2-aminoprop-1-ene-1,1,3-tricarbonitrile (1) as the key starting material for many heterocyclization reactions.

METHOD

Muticoponent reactions were adopted using compound 1 to get different pyridine derivatives that were capable for different heterocyclization reactions.

RESULTS

Antiproliferative evaluations and c-Met kinase, Pim-1 kinse inhibitions were perform where some compounds gave high activities.

CONCLUSION

Compounds that showed high antiprolifeative activity were tested gor c-Met-independent and the results showed that compounds 5c, 5e, 5f, 7c, 7f and 16d were more active than foretinib. The Pim-1 kinase inhibition activity of some selected compounds showed that compounds 5e and 16c were high potent to inhibit Pim-1 activity.

摘要

背景

在广泛的吡啶类化合物中,3-氰基吡啶因其广泛的药理活性,尤其是治疗活性,而受到特别关注。许多含有吡啶核的药物在市场上已经被发现。

目的

本工作的目的是合成不仅具有抗肿瘤活性而且还具有激酶抑制剂活性的靶分子。为了实现这一目标,我们的策略是使用 2-氨基丙-1-烯-1,1,3-三腈(1)作为许多杂环化反应的关键起始原料,合成一系列 3-氰基吡啶衍生物。

方法

采用多组分反应,使用化合物 1 得到不同的吡啶衍生物,这些衍生物能够进行不同的杂环化反应。

结果

进行了抗增殖评估和 c-Met 激酶、Pim-1 激酶抑制实验,其中一些化合物表现出了较高的活性。

结论

显示出高抗增殖活性的化合物被测试了对 c-Met 的依赖性,结果表明化合物 5c、5e、5f、7c、7f 和 16d 比 foretinib 更具活性。一些选定化合物的 Pim-1 激酶抑制活性表明,化合物 5e 和 16c 对抑制 Pim-1 活性具有高潜力。

相似文献

1
Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations.2-氨基丙-1-烯-1,1,3-三腈衍生的吡啶和螺吡啶衍生物的合成及其 c-Met 激酶抑制活性和抗增殖活性评价。
Anticancer Agents Med Chem. 2018 Feb 7;17(14):1951-1962. doi: 10.2174/1871520617666170725153523.
2
New Approaches for the Synthesis of Fused Thiophene, Pyrazole, Pyran and Pyridine Derivatives with Anti-Proliferative Together with c-Met Kinase and Prostate Cancer Cell Inhibitions.具有抗增殖、c-Met 激酶和前列腺癌细胞抑制活性的稠合噻吩、吡唑、吡喃和吡啶衍生物的合成新方法。
Anticancer Agents Med Chem. 2021;21(13):1751-1766. doi: 10.2174/1871520620999201110191056.
3
Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione.用环己-1,4-二酮衍生的 5,6,8,9-四氢吡嗪并[5,1-b]喹唑啉-7(3H)-酮衍生物合成和评估新杂环衍生物及其抗增殖活性。
Anticancer Agents Med Chem. 2021;21(4):468-486. doi: 10.2174/1871520620666200523162549.
4
New Approaches for the Uses of Cyclohexan-1,4-dione for the Synthesis of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-b]pyridine Derivatives used as Potential Anti-prostate Cancer Agents and Pim-1 Kinase Inhibitors.环己烷-1,4-二酮用于合成用作潜在抗前列腺癌药物和Pim-1激酶抑制剂的5,6,7,8-四氢苯并[4,5]噻吩并[2,3-b]吡啶衍生物的新方法。
Anticancer Agents Med Chem. 2018;18(12):1736-1749. doi: 10.2174/1871520618666180604091358.
5
Synthesis of Tetrahydrobenzo[]thiophene-3-carbohydrazide Derivatives as Potential Anti-cancer Agents and Pim-1 Kinase Inhibitors.四氢苯并噻吩-3-甲酰肼衍生物的合成及其作为潜在抗癌药物和 Pim-1 激酶抑制剂的研究。
Anticancer Agents Med Chem. 2019;19(14):1737-1753. doi: 10.2174/1871520619666190402153429.
6
Multi-Component Reactions of Cyclohexan-1,3-dione: Synthesis of Fused Pyran, Pyridine, Thiophene and Pyrazole Derivatives with c-Met, Anti-Proliferative Activities.环己烷-1,3-二酮的多组分反应:c-Met、抗增殖活性的稠合吡喃、吡啶、噻吩和吡唑衍生物的合成。
Anticancer Agents Med Chem. 2021;21(17):2443-2463. doi: 10.2174/1871520621666210112115128.
7
Heterocyclization of Thiophenes Derived from Estrone Followed by Cytotoxic, HTRF Kinase and Pim-1 Kinase Evaluations.雌酮衍生噻吩的杂环化反应及其细胞毒性、HTRF激酶和Pim-1激酶活性评估
Anticancer Agents Med Chem. 2018;18(12):1711-1728. doi: 10.2174/1871520618666180507141045.
8
Heterocyclization of 2-(2-phenylhydrazono)cyclohexane-1,3-dione to Synthesis Thiophene, Pyrazole and 1,2,4-triazine Derivatives with Anti-Tumor and Tyrosine Kinase Inhibitions.2-(2-苯腙基)环己烷-1,3-二酮的杂环化合成噻吩、吡唑和 1,2,4-三嗪衍生物及其抗肿瘤和酪氨酸激酶抑制活性。
Anticancer Agents Med Chem. 2020;20(10):1209-1220. doi: 10.2174/1871520620666200310093911.
9
Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors.环已烷-1,3-二酮在合成 1,2,4-三嗪衍生物作为抗增殖剂和酪氨酸激酶抑制剂中的用途。
Bioorg Chem. 2020 Apr;97:103667. doi: 10.1016/j.bioorg.2020.103667. Epub 2020 Feb 13.
10
Heterocyclization of 2-Arylidenecyclohexan-1,3-dione: Synthesis of Thiophene, Thiazole, and Isoxazole Derivatives with Potential Antitumor Activities.2-芳亚基环己烷-1,3-二酮的杂环化反应:具有潜在抗肿瘤活性的噻吩、噻唑和异噁唑衍生物的合成。
Anticancer Agents Med Chem. 2020;20(3):335-345. doi: 10.2174/1871520619666190730103425.

引用本文的文献

1
Synthesis and Aminomethylation of 2-Amino-4-(2-chlorophenyl)-6-(dicyanomethyl)-1,4-dihydropyridine-3,5-dicarbonitrile -Methylmorpholinium Salt.2-氨基-4-(2-氯苯基)-6-(二氰基甲基)-1,4-二氢吡啶-3,5-二甲腈-甲基吗啉鎓盐的合成与氨甲基化反应
Russ J Gen Chem. 2022;92(5):779-790. doi: 10.1134/S1070363222050061. Epub 2022 Jun 14.